Allogene Therapeutics (ALLO) has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus.
The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will evaluate the safety and efficacy of ALLO-329 in patients with lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.
The trial design also is intended to increase CAR-T cell expansion in patients and prevent rejection by having two distinct lymphodepletion arms, with patients in one part of the study receiving a dose of cyclophosphamide alone which is used by rheumatologists and the other that eliminates lymphodepletion entirely, the company said.
Allogene shares were 0.3% lower in recent trading.
Price: 1.95, Change: +0.02, Percent Change: +0.78
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.